此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估败血症的免疫功能障碍

2026年9月21日 更新者:University of Minnesota

Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the ~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective of this study is to define the cellular and molecular mechanisms driving the dysfunction and reprogramming of T cells and B cells that mediate cellular and humoral immunity using a combination of phenotypic, functional, genomic, and metabolomic assays.

研究概览

地位

招聘中

条件

研究类型

观察性的

注册 (估计的)

150

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Mrunmayi Tilak
  • 电话号码:612-624-9990
  • 邮箱:mtilak@umn.edu

学习地点

    • Minnesota
      • Minneapolis、Minnesota、美国、55455
        • 招聘中
        • University of Minnesota
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients with and without sepsis in the ICU, compared to healthy volunteers

描述

ICU With Sepsis Inclusion Criteria:

  • Age ≥ 18

  • Presumed diagnosis of sepsis, defined as "patients with life-threatening organ dysfunction caused by a dysregulated host response to infection"

  • Patients in the ICU who meet 2 or more of the quick SOFA (qSOFA) definition along with organ dysfunction:

    1. Respiration rate ≥ 22 breaths/min and/or mechanically ventilated
    2. An alteration in mental status
    3. Systolic blood pressure of less than 100 mm Hg and/or receiving inotropes to maintain blood pressure AND/OR
    1. An acute change in SOFA score ≥2 points, consequent to the infection (can assume SOFA score = 0 in patients with no pre-existing organ dysfunction)

ICU Without Sepsis Inclusion Criteria:

  • Age ≥ 18
  • Patients requiring care at a M Health Fairview ICU due to high acuity of illness and no other evidence of sepsis

Healthy Volunteer Inclusion Criteria

  • Age greater or equal to 18
  • ASA status 1, 2 or 3
  • May include patients who are receiving dialysis in an outpatient setting

Exclusion Criteria (all groups):

  • Active cancer with chemotherapy and/or radiation treatment within the past 6 weeks
  • Medication usage that includes immunosuppressive drugs, biologic agents, cytokines, growth factor and interleukins
  • Steroid medication usage of > 300mg hydrocortisone per day (equivalent of > 20mg prednisone). Patients with chronic steroid use will be excluded, however patients who have had stress dose steroids administered following admission will be included.
  • Patients with a history of, or who currently have evidence of autoimmune disease, including but not limited to: myasthenia gravis, Guillain Barré syndrome, systemic lupus erythematosus, multiple sclerosis, scleroderma, ulcerative colitis, Crohn's disease, autoimmune hepatitis, Wegener's granulomatosis, HIV/AIDS, etc.
  • Patients with active or a history of acute or chronic lymphocytic leukemia
  • Known history of chronic hepatitis B (HBV) infection and not on treatment with HBV nucleoside analogues prior to the current hospitalization, or HBV DNA > 100 IU/mL
  • Known history of infection with hepatitis C (HCV) and currently undergoing treatment for HCV infection or has detectable HCV RNA
  • Participation in another investigational interventional drug study within the past 4 weeks
  • Current pregnancy
  • Current incarceration

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_CONTROL
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
健康志愿者

No intervention is included in this study

ICU败血症患者

No intervention is included in this study

没有败血症的ICU患者

No intervention is included in this study

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
EliSpot - Day 1
大体时间:Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
EliSpot - Day 4
大体时间:Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
EliSpot - Day 7
大体时间:Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
EliSpot - Day 14
大体时间:Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
EliSpot - Day 21
大体时间:Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
EliSpot - Day 28
大体时间:Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Ex Vivo TNF Production - Day 1
大体时间:Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Ex Vivo TNF Production - Day 4
大体时间:Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Ex Vivo TNF Production - Day 7
大体时间:Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Ex Vivo TNF Production - Day 14
大体时间:Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Ex Vivo TNF Production - Day 21
大体时间:Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Ex Vivo TNF Production - Day 28
大体时间:Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Flow Cytometry of Peripheral Blood Leukocytes - Day 1
大体时间:Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Flow Cytometry of Peripheral Blood Leukocytes - Day 4
大体时间:Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Flow Cytometry of Peripheral Blood Leukocytes - Day 7
大体时间:Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Flow Cytometry of Peripheral Blood Leukocytes - Day 14
大体时间:Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Flow Cytometry of Peripheral Blood Leukocytes - Day 21
大体时间:Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Flow Cytometry of Peripheral Blood Leukocytes - Day 28
大体时间:Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Quantification of Cytokines in Serum - Day 1
大体时间:Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Quantification of Cytokines in Serum - Day 4
大体时间:Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Quantification of Cytokines in Serum - Day 7
大体时间:Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Quantification of Cytokines in Serum - Day 14
大体时间:Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Quantification of Cytokines in Serum - Day 21
大体时间:Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Quantification of Cytokines in Serum - Day 28
大体时间:Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Quantification of Chemokines in Serum - Day 1
大体时间:Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Quantification of Chemokines in Serum - Day 4
大体时间:Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Quantification of Chemokines in Serum - Day 7
大体时间:Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Quantification of Chemokines in Serum - Day 14
大体时间:Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Quantification of Chemokines in Serum - Day 21
大体时间:Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Quantification of Chemokines in Serum - Day 28
大体时间:Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Transcriptional Profiling - Day 1
大体时间:Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Transcriptional Profiling - Day 4
大体时间:Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Transcriptional Profiling - Day 7
大体时间:Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Transcriptional Profiling - Day 14
大体时间:Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Transcriptional Profiling - Day 21
大体时间:Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Transcriptional Profiling - Day 28
大体时间:Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
CBC - Day 1
大体时间:Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
CBC - Day 4
大体时间:Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
CBC - Day 7
大体时间:Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
CBC - Day 14
大体时间:Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
CBC - Day 21
大体时间:Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
CBC - Day 28
大体时间:Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Thomas Griffith, PhD、University of Minnesota

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年3月1日

初级完成 (估计的)

2028年11月1日

研究完成 (估计的)

2028年11月1日

研究注册日期

首次提交

2025年8月26日

首先提交符合 QC 标准的

2025年8月26日

首次发布 (实际的)

2025年9月4日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月21日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • URO-2025-34202

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅